Propionyl carnitine

Drug Profile

Propionyl carnitine

Alternative Names: Dromos; Levocarnitine proprionate; Levocarnitine proprionate hydrochloride; PLC; Propionyl-L-carnitine; Propionyl-L-carnitine HCl; Propionyl-L-carnitine hydrochloride; ST 261

Latest Information Update: 07 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sigma-tau SpA
  • Developer Lees Pharmaceutical Holdings; sigma-tau SpA
  • Class Anti-ischaemics; Heart failure therapies; Ischaemic heart disorder therapies; Small molecules; Trimethyl ammonium compounds; Vascular disorder therapies; Vitamins
  • Mechanism of Action Free radical scavengers; Pyruvate dehydrogenase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Peripheral arterial occlusive disorders
  • Discontinued Angina pectoris; Heart failure; Kidney disorders; Myocardial ischaemia; Ulcerative colitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 02 Apr 2012 sigma-tau plans a phase III trial for Ulcerative colitis in Austria, France, Germany, Hungary, Latvia, Lithuania, Poland and Spain (NCT01567956)
  • 19 Mar 2012 sigma-tau plans a phase III trial for Ulcerative colitis in Belgium, Czech Republic, Israel, Italy, Netherlands, Romania, Russia and Slovakia (NCT01538251)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top